Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Ludwig Center for Molecular Oncology at MIT, Cambridge, Massachusetts.
Cancer Res. 2019 Dec 1;79(23):5944-5957. doi: 10.1158/0008-5472.CAN-19-1165. Epub 2019 Sep 3.
Systemic dissemination of tumor cells often begins long before the development of overt metastases, revealing the inefficient nature of the metastatic process. Thus, already at the time of initial clinical presentation, many patients with cancer harbor a myriad disseminated tumor cells (DTC) throughout the body, most of which are found as mitotically quiescent solitary cells. This indicates that the majority of DTCs fail, for still unknown reasons, to initiate rapid proliferation after entering foreign tissue, which likely contributes significantly to the inefficiency of metastasis formation. Here, we showed that extracellular matrix (ECM) components of the host parenchyma prevented proliferation of DTCs that had recently infiltrated foreign tissue by binding to syndecan receptors expressed on the surface of these cells. This led to the recruitment of the Par-3:Par-6:atypical PKC protein complex, a critical regulator of cell polarity, to the plasma membrane and release of Par-1 kinase into the cytosol. Cytosolic Par-1 bound, phosphorylated, and inactivated KSR scaffolding proteins ultimately inhibited Ras/ERK signaling and, in turn, cell proliferation. Inhibition of the syndecan-mediated signaling restored the proliferation of otherwise dormant DTCs, enabling these cells to efficiently colonize foreign tissues. Intriguingly, naturally aggressive cancer cells overcame the antiproliferative effect of syndecan-mediated signaling either by shutting down this signaling pathway or by activating a proproliferative signaling pathway that works independent of syndecan-mediated signaling. Collectively, these observations indicate that the proliferative arrest of DTCs is attributable, in part, to the syndecan-mediated ligation of ECM proteins. SIGNIFICANCE: This study identifies a novel signaling pathway that regulates the proliferative dormancy of individual disseminated tumor cells. http://cancerres.aacrjournals.org/content/canres/79/23/5944/F1.large.jpg.
肿瘤细胞的系统性扩散通常在明显转移发生之前很久就开始了,这揭示了转移过程的低效性质。因此,在初始临床表现时,许多癌症患者的体内已经存在无数的弥散性肿瘤细胞(DTC),其中大多数是处于有丝分裂静止的单个细胞。这表明,大多数 DTC 由于未知原因,在进入异组织后未能启动快速增殖,这很可能是转移形成效率低下的主要原因。在这里,我们表明,宿主实质的细胞外基质(ECM)成分通过与这些细胞表面表达的 syndecan 受体结合,阻止了最近浸润到异组织中的 DTC 的增殖。这导致 Par-3:Par-6:非典型 PKC 蛋白复合物的募集,这是细胞极性的关键调节剂,到质膜,并将 Par-1 激酶释放到细胞质中。细胞质中的 Par-1 结合、磷酸化并失活 KSR 支架蛋白,最终抑制 Ras/ERK 信号通路,并反过来抑制细胞增殖。抑制 syndecan 介导的信号通路恢复了 otherwise dormant DTC 的增殖能力,使这些细胞能够有效地殖民异组织。有趣的是,自然侵袭性癌细胞通过关闭这条信号通路或激活独立于 syndecan 介导的信号通路的促增殖信号通路,克服了 syndecan 介导的信号通路的增殖抑制作用。总的来说,这些观察结果表明,DTC 的增殖停滞部分归因于 syndecan 介导的细胞外基质蛋白的连接。意义:本研究确定了一种调节单个弥散性肿瘤细胞增殖休眠的新信号通路。